On July 21, 2021, Shanghai Escugen Biotech Co., Ltd. announced that it has officially received the approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the clinical trial application (IND) of its recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate (acceptance number CXSL2101069).

On August 24, 2020, Shanghai Escugen Biotech Co., Ltd. (hereinafter referred to as "Escugen Biotech") announced that it has recently completed a Pre-A financing round of tens of millions of yuan.